Medtronic

Tailored AF ablation in less time

Durable, dual-energy ablation for PVI and PVI+[1,2]

PVI + additional linear ablation with the Sphere-9™ catheter resulted in numerically higher long-term efficacy compared to patients treated using a similar ablation strategy with the RF control[†,1]

(75% vs. 68%, p = 0.21; N = 204 and N = 124, respectively)

Significantly faster ablation time for all lesion sets performed with the Sphere-9 catheter compared to the RF control.[1] (p < 0.0001 for all)

Effective,[1] durable[2] lesions

Energy type by lesion set[1]



100%
Acute success of linear ablation performed with the Sphere-9 catheter[1]

Durability◊,2

PVI¶
97% per vein
(N = 124 PVs, 31 patients)

All linear lesions¶
91%
(N = 91 patients)

LA roof line¶ 100%
(N = 30)

CTI line# 87%
NRΔ

Mitral line# 68%
NRΔ

† "PVI +" ablation strategies include PVI + at least one adjunctive ablation lesion set of the following: left atrial roof and posterior wall, mitral line, cavotricuspid isthmus (CTI) line.
‡ All RF applications were performed for roof lines.
§ The Sphere-9 catheter is indicated for ablation of cavotricuspid isthmus dependent atrial flutter using radiofrequency ablation only.

◊ Durability as assessed by protocol-mandated, high-density invasive remapping 96 ± 43 days after the index procedure. Further studies in larger patient cohorts are needed to understand the impact of lesion durability and long-term maintenance of sinus rhythm.
¶ Data represents subset of patients treated with the optimized PULSE3 PFA waveform.

Data represents patients treated with any PFA waveform (PULSE1, PULSE2, or PULSE3). Durability by PFA waveform not reported.
Δ Number of patients who received CTI line or mitral line ablation in index procedures who reported for invasive remapping was not reported. N = 121 patients received CTI line ablation and N=78 patients received mitral line ablation at index procedure.

1. Mansour M, Sharma D, Kiehl E, et al. Impact of linear ablation in persistent atrial fibrillation using a dual-energy, wide-footprint catheter: Analysis from the SPHERE Per-AF randomized trial. *Heart Rhythm*. Published online February 6, 2026.
2. Reddy VY, Peichl P, Anter E, et al. A Focal Ablation Catheter Toggling Between Radiofrequency and Pulsed Field Energy to Treat Atrial Fibrillation. *JACC Clin Electrophysiol*. August 2023;9(8 Pt 3):1786–1801.

This material should not be considered the exclusive source of information, it does not replace or supersede information contained in the device manual(s). Please note that the intended use of a product may vary depending on geographical approvals.See the device manual(s) for detailed information regarding the intended use, the (implant) procedure, indications, contraindications, warnings, precautions, and potential adverse events. For a MRI compatible device(s), consult the MRI information in the device manual(s) before performing a MRI.If a device is eligible for eIFU usage, instructions for use can be found at Medtronic's website manuals.medtronic.com. Manuals can be viewed using a current version of any major internet browser. For best results, use Adobe Acrobat® Reader with the browser.Medtronic products placed on European markets comply with EU and UK legislation (if applicable) on medical devices.For any further information, contact your local Medtronic representative.Medtronic medical devices marketed in Spain are in compliance with the Spanish legislation in force.

Medtronic

Europe
Medtronic International Trading Sàrl.
Route du Molliau 31
Case postale
CH-1131 Tolochenaz
Tel: +41 (0)21 802 70 00
Fax: +41 (0)21 802 79 00

medtronic.eu

23215673-en-emea ©2026 Medtronic. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.